Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Utah: - Farmington Health Center — Farmington, Utah
- University of Utah Sugarhouse Health Center — Salt Lake City, Utah
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- South Jordan Health Center — South Jordan, Utah
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Utah: - Site 10 — Salt Lake City, Utah
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Utah: - Farmington Health Center — Farmington, Utah
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- South Jordan Health Center — South Jordan, Utah
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
- University of Utah Health Huntsman Cancer Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT05985655
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Academic/Other
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of sh…
Sponsor: University of Chicago
NCT ID: NCT04683653
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
Sponsor: University of Utah
NCT ID: NCT07044635
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) an…
Sponsor: Eli Lilly and Company
NCT ID: NCT06400472
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Sponsor: ALX Oncology Inc.
NCT ID: NCT07085091
Sites in Utah: - ALX Center 4 — West Valley City, Utah
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT07517198
Sites in Utah: - START Mountain Region — West Valley City, Utah
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Utah: - Massive Bio SYNERGY-AI site — Salt Lake City, Utah
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
NA Recruiting NIH
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a comm…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07281430
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
NA Recruiting Academic/Other
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Utah: - George E. Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
NA Recruiting Academic/Other
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cerv…
Sponsor: University of Colorado, Denver
NCT ID: NCT04916990
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah